Movicol® Unidose

Polyethylene glycol 3350 with electrolytes, the active ingredient in Movicol® Unidose, is an osmotic laxative presented as an oral powder for solution (single‑dose sachet) for oral use. It treats chronic and occasional constipation and is used to prepare the bowel for diagnostic procedures.

GNH USA supplies Movicol® Unidose as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movicol® Unidose, an osmotic laxative, is indicated for conditions that require increased intestinal water content.

Chronic constipation: softens stool and promotes regular bowel movements in patients with persistent constipation. Occasional constipation: provides rapid relief of infrequent difficulty passing stool. Bowel preparation for diagnostic procedures: clears the colon to improve visualization during colonoscopy or imaging studies.

Common Side Effects: - Abdominal bloating - Flatulence - Nausea - Abdominal cramps - Diarrhoea - Thirst

Serious or Rare Side Effects: - Severe electrolyte imbalance (e.g., hyponatraemia, hypokalaemia) - Dehydration - Allergic reactions such as rash or angioedema - Severe abdominal pain or rectal bleeding

Before using Movicol® Unidose, consider the following precautions.

Assess renal function: avoid or adjust use in patients with severe renal impairment. Monitor electrolytes: especially sodium and potassium in at‑risk individuals. Use caution in the elderly: increased susceptibility to dehydration and electrolyte shifts. Avoid in known hypersensitivity: do not use if the patient is allergic to polyethylene glycol or any electrolyte component. Do not exceed recommended dose: follow prescriber instructions precisely. Store at ambient temperature: keep in the original pack, protect from moisture.

Movicol® Unidose may interact with other medicines; review the following.

Major Interactions (Avoid): - Concomitant high‑dose diuretics: heightened risk of electrolyte disturbances. - Use with other osmotic laxatives: may cause excessive fluid loss. - Co‑administration with nephrotoxic drugs (e.g., NSAIDs) in compromised kidneys.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium: increased osmotic load. - Lithium therapy: altered lithium levels due to sodium shifts. - Certain antibiotics (e.g., quinolones): reduced absorption if taken simultaneously.